The impact of abacavir on lipids and lipodystrophy.
Moyle
Graeme J
GJ
Chelsea & Westminster Hospital, London, UK.
D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000188:drug therapy; D003430:Cross-Sectional Studies; D015224:Dideoxynucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005260:Female; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D015994:Incidence; D019259:Lamivudine / Q000009:adverse effects / Q000627:therapeutic use*; D008060:Lipodystrophy / Q000453:epidemiology / Q000209:etiology*; D008297:Male; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D000099227:Abacavir
D015224:Dideoxynucleosides; D019259:Lamivudine; D000099227:Abacavir